Investors facing significant losses from Capricor Therapeutics are encouraged to lead a class action lawsuit by the September 28, 2026 deadline.

Investors who have suffered significant losses with Capricor Therapeutics, Inc. are encouraged to lead a shareholder class action lawsuit before the upcoming deadline.

Investors of Capricor Therapeutics have been informed about a class action lawsuit concerning alleged securities fraud and clinical data issues, with a deadline to respond.

Capricor Therapeutics will show HOPE-3 skeletal and cardiac outcomes data at the World Muscle Society Congress ahead of its November BLA action date.

What did the FDA's three-month extension add to the deramiocel BLA? 24-month HOPE-3 data, a narrower proposed indication, a November 22, 2026 PDUFA. $CAPR

Capricor Therapeutics Inc. is dealing with an FDA review extension for deramiocel amidst an ongoing securities class action. Investors must prepare for a lead plaintiff deadline.

Capricor Therapeutics (CAPR) will present 24‑month data from the Phase 3 HOPE-3 trial and its open-label extension of Deramiocel in Duchenne muscular dystrophy at the 2026 World Muscle Society Congress in Hiroshima, Japan.The late-breaking presentations will include skeletal muscle and cardiac outcomes, a delayed-start analysis and natural history comparisons that were included in a recent major amendment to the Deramiocel BLA, which has a PDUFA target action date of November 22, 2026. HOPE-3 randomized 106 patients; 82 reached 24 months (40 originally on Deramiocel, 42 on placebo). The trial met its primary endpoint, with Deramiocel slowing decline in upper limb function by 54% versus placebo on PUL 2.0 (p=0.03). Capricor will also present two preclinical posters from its StealthX exosome platform.

Investors in Capricor Therapeutics facing significant losses are strongly encouraged to act before the September 28 deadline for the class action lawsuit.

B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.

Hagens Berman notifies Capricor Therapeutics investors of the FDA's review extension for Deramiocel, coinciding with a securities class action and lead plaintiff deadline.

Investors of Capricor Therapeutics are alerted about a recent class action lawsuit following a significant stock drop. The deadline for claims approaches on September 28, 2026.

Die FDA verlegt den Prüftermin für Capricors Deramiocel auf den 22. November. Zusätzliche HOPE-3-Daten verlängern das Verfahren.

Capricor Therapeutics investors faced a critical deadline for a class action lawsuit following significant losses. The time to act is now.

Capricor Therapeutics has come under fire with a class action lawsuit claiming securities fraud after a staggering 64% drop in stock prices due to misleading clinical data about their product, Deramiocel.

Hagens Berman announces an FDA review extension for Capricor's Deramiocel while investors face a September deadline for a class action lawsuit.

Investors of Capricor Therapeutics, Inc. impacted by losses can lead a class action lawsuit. Deadline is September 28, 2026.

The FDA extended its review of deramiocel for Duchenne muscular dystrophy to November 22, 2026, after accepting additional HOPE-3 data.

Oppenheimer raises Capricor to Outperform on clearer path for deramiocel. $54 target, PDUFA Nov 22 after upper-limb focus.

Capricor Therapeutics has been hit with a class action lawsuit after a staggering 64% drop in stock price following alleged fraud claims regarding clinical data integrity.